CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 116 enrolled
Drug / intervention
N-Acetylcysteine +2 moredrug
Likely dose
N-Acetylcysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01005810
NCT01005810Phase 2Completed
CompareCT.gov

A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents

Medical University of South Carolina·interventional·Posted Nov 2, 2009·Updated Nov 21, 2018

In Brief

A Phase 2 clinical trial evaluating N-Acetylcysteine, placebo, and 1 other intervention for Cannabis Dependence. Completed, enrolled 116 participants across 1 site.

Detailed Summary

This study is investigating how N-Acetylcysteine (NAC), an over-the-counter medication, will reduce marijuana use when combined with Contingency Management, a behavioral treatment. It is hypothesized that marijuana dependent adolescents who are treated with NAC will use less marijuana during treatment when compared to adolescents who receive a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2009
Enrollment StartSep 1, 2009
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.7 years ago

Interventions

N-Acetylcysteinedrug

1200 mg twice daily for 8 weeks

placebodrug

2 capsules twice daily for 8 weeks

Contingency Managementbehavioral

rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule